- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
Nanostart (OTCQX: NASRY)-holding MagForce AG (FSE: MF6), a leading medical technology company focusing on nanomedicine in oncology, has completed a share placement from its authorized capital. In connection with the transaction, the company's nominal capital increased from EUR 4,070,681, divided into 4,070,681 no par value common shares in bearer form with an imputed nominal value of EUR 1.00 by EUR 56,360.00 to EUR 4,127,041.00.
Dr. Peter Heinrich, CEO of MagForce AG, along with international investors participated in the share placement. The company excluded subscription rights to existing shareholders by its authority under sec. 6 para. 4 of its articles of incorporation (Satzung).
A total of 56,360.00 new common bearer shares with profit participation rights dating from January 1, 2011 were issued in the private placement at a price of EUR 12.42 per share. The gross proceeds of the capital increase in the amount of approx. EUR 700,000.00 will go to the company and will be used to finance its further growth.
About Nanostart AG
Nanostart AG (OTCQX: NASRY), headquartered in the German financial capital of Frankfurt, is a leading nanotechnology investment company, with portfolio companies spanning the globe from Silicon Valley to Singapore. The company provides venture capital financing for nanotechnology companies in various growth phases with a focus on innovation-driven industries of the future such as cleantech, life sciences and IT/electronics. Through its subsidiary Nanostart Asia (www.nanostart-asia.com) and the venture capital fund in Singapore, Nanostart is proud to be the investment partner of the Singaporean government. For further information, please visit www.nanostart.de.
MagForce AG (FSE: MF6), is a leading medical technology company focusing on nanomedicine in oncology. The company’s proprietary procedure, NanoTherm therapy, enables the targeted treatment of solid tumors through the intratumoral release of heat from magnetic nanoparticles. NanoTherm®, NanoPlan®, and NanoActivator™ are components of the therapy and have received EU-wide regulatory approval as medical devices for the treatment of brain tumors. MagForce, NanoTherm, NanoPlan and NanoActivator are trademarks of MagForce AG in selected countries. For further information, please visit: www.magforce.de.
This notice constitutes neither an offer to sell nor a solicitation of offers to purchase or subscribe to securities. There will be no public offering of securities of Nanostart AG in conjunction with the existing listing of its shares in the “Entry Standard” segment of the regulated unofficial market (Freiverkehr) on the Frankfurt Stock Exchange. This notice does not constitute a securities prospectus. Neither this notice nor the information contained within is intended for direct or indirect distribution within Canada, Australia or Japan.
For more information, please click here
Dr. Hans Joachim Duerr
Head of Corporate Communications
D-60313 Frankfurt, Germany
phone: +49 (0)69-21 93 96 111
fax: +49 (0)69-21 93 96 150
Copyright © Nanostart AGIf you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
News and information
Chivalrous Knight Does Pro Bono June 27th, 2015
Exagan Raises €5.7 Million to Produce High-efficiency GaN-on-Silicon Power-switching Devices on 200mm Wafers: Leti-and-Soitec Spinout Focused on Becoming Leading European Source Of GaN Devices for Solar, Automotive, Telecoms and Infrastructure June 25th, 2015